COVID-19 vaccine effectiveness
(Randomized evidence)

If you want to see all comparisons, please click here

Sinopharm - Wuhan-WIV04 COVID-19 Vaccine vs Placebo

You will find below the forest plots for this comparison with the general characteristics and risk of bias assessment for all RCTs identified.
Of note all trials may not be included in the synthesis.

Forest plots
(last update: 2021-06-04)

Evidence profile
2021-06-11

Summary of findings
2021-06-11

Trial Type Comparisons Design Participants Sample size Overall risk
of bias
Highest assessment
Full description
Intervention 1 Intervention 2
NCT04510207, ChiCTR2000034780
Sinopharm - China National Biotec Group Company Limited
Al Kaabi N, JAMA, 2021

Full text
Commentary
Commentary
Inactivated virus

WIV04

HBO2

Placebo

RCT
Phase 3
Healthy adults free of known COVID-19 or HIV infection at 3 centres in United Arab Emirates and Bahrain N=40411
Some concerns
Details

Full description

ChiCTR2000031809
Wuhan Institute of Biological Products Co Ltd./Sinopharm
Xia S, JAMA, 2020

Full text
Commentary
Inactivated virus

Inactivated 2.5mcg-3doses

Inactivated 5mcg-3doses

Inactivated 10mcg-3doses

Inactivated 5mcg-D0/14

Inactivated 5mcg-D0/21

Placebo

RCT
Phase 1
Healthy adults, aged 18 to 59 years, without history ofSARS-CoV(via on-site inquiry) or SARS-CoV-2 infection (via serologicaland nucleic acid test N=320
Low
Details

Full description